» Articles » PMID: 32203012

Transfusion-transmitted Cytomegalovirus: Behaviour of Cell-free Virus During Blood Component Processing. A Study on the Safety of Labile Blood Components in Switzerland

Overview
Journal Blood Transfus
Specialty Hematology
Date 2020 Mar 24
PMID 32203012
Citations 2
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Nowadays, most blood products are leukocyte-reduced. After this procedure, the residual risk for transfusion transmitted cytomegalovirus (TT-CMV) is mostly attributed to cell-free viruses in the plasma of blood donors following primary infection or viral reactivation. Here, objectives are: 1) to study the behaviour of cell-free CMV through the blood component processing; 2) to determine the anti-CMV seroprevalence, the level of viremia, the window-period in blood donor population; and 3) to identify cases of TT-CMV in bone marrow transplant (BMT) recipients.

Materials And Methods: Cell-free CMV was injected into blood bags originating from regular donors. Blood components were processed according to either the CompoSelect or the CompoFlow (Fresenius Kabi AG) techniques. Samples were analysed at each step for presence of virus DNA using quantitative polymerase chain reaction (PCR). The anti-CMV seroprevalence in our donor population was taken from our donor data system. The viremia was assessed in pooled plasmas samples from routine donations by quantitative PCR. Medical charts of 165 BMT anti-CMV seronegative recipients/anti-CMV seronegative donors who received CMV-unscreened blood products were reviewed.

Results: Cell-free CMV passes without any decrease in viral load through all stages of blood processing. The anti-CMV seroprevalence was 46.13%. Four DNA positive samples out of 42,240 individual blood donations were identified (0.009%); all had low levels of viremia (range 11-255 IU/mL). No window-period donation was identified. No TT-CMV was found.

Discussion: Cell-free CMV remains a concern with current blood component processing as it passes through all the processes. However, since low levels of CMV DNA were identified in the donations tested, and no BMT recipients had TT-CMV, the residual threat of TT-CMV after leukocyte reduction appears to be very low.

Citing Articles

Prevalence and investigation of Cytomegalovirus (HCMV) in blood donors from the main blood establishment in Rio de Janeiro/Brazil.

Oliveira A, Pereira J, Nunes G, Sousa Junior I, Sarmento D, Lopes J Braz J Infect Dis. 2025; 29(2):104508.

PMID: 39922051 PMC: 11848753. DOI: 10.1016/j.bjid.2025.104508.


Unveiling microbial worlds: exploring viral metagenomics among waste pickers at Latin America's largest dumpsite.

Cruvinel V, Carvalho E, Alves D, Marques C, Bezerra R, Giovanetti M Rev Inst Med Trop Sao Paulo. 2024; 66:e49.

PMID: 39194141 PMC: 11348794. DOI: 10.1590/S1678-9946202466049.


Human Cytomegalovirus Seroprevalence Among Blood Donors in the Madinah Region, Saudi Arabia.

Mahallawi W, Khabour O, Al-Saedi A, Almuzaini Z, Ibrahim N Cureus. 2022; 14(2):e21860.

PMID: 35265404 PMC: 8897812. DOI: 10.7759/cureus.21860.

References
1.
Ziemann M, Juhl D, Gorg S, Hennig H . The impact of donor cytomegalovirus DNA on transfusion strategies for at-risk patients. Transfusion. 2013; 53(10):2183-9. DOI: 10.1111/trf.12199. View

2.
Bowden R, Sayers M, Flournoy N, Newton B, Banaji M, Thomas E . Cytomegalovirus immune globulin and seronegative blood products to prevent primary cytomegalovirus infection after marrow transplantation. N Engl J Med. 1986; 314(16):1006-10. DOI: 10.1056/NEJM198604173141602. View

3.
Vamvakas E . Is white blood cell reduction equivalent to antibody screening in preventing transmission of cytomegalovirus by transfusion? A review of the literature and meta-analysis. Transfus Med Rev. 2005; 19(3):181-99. DOI: 10.1016/j.tmrv.2005.02.002. View

4.
Kaariainen L, KLEMOLA E, PALOHEIMO J . Rise of cytomegalovirus antibodies in an infectious-mononucleosis-like syndrome after transfusion. Br Med J. 1966; 1(5498):1270-2. PMC: 1844561. DOI: 10.1136/bmj.1.5498.1270. View

5.
Ziemann M, Heuft H, Frank K, Kraas S, Gorg S, Hennig H . Window period donations during primary cytomegalovirus infection and risk of transfusion-transmitted infections. Transfusion. 2013; 53(5):1088-94. DOI: 10.1111/trf.12074. View